Capricor Therapeutics, Inc. (CAPR): שולי רווח תפעולי

סמל מסחרי של Capricor Therapeutics Inc. (CAPR)

Capricor Therapeutics (CAPR) is mitigating risks by developing cell therapy for rare muscle pathologies. GURU.Markets analytics provide the historical operating margin level, where 0.00 describes the current status of the metric. Business prospects depend on FDA approval of deramiocel and the partnership with Nippon Shinyaku, as the company completes clinical trials of its innovative product for the treatment of Duchenne muscular dystrophy prior to commercialization.

CAPR: שולי רווח תפעולי Capricor 04.07.2022 - 19.11.2026

Capricor Therapeutics Inc. - פילוחים אנליטיים ומדדי מפתח (CAPR)

ניתוח ראשוני של החברה:Capricor Therapeutics Inc., CAPR
מוצר עיקרי של Capricor Therapeutics, Inc.

Capricor Therapeutics (CAPR) specializes in developing innovative cell therapy methods for cardiac and muscle pathologies. An analysis of the projected operating margin allows for an assessment of the efficiency of cost management regarding drug development. This metric is calculated as the ratio of operating profit to revenue before taxes and interest. Growth in this metric confirms the business's resilience to costs amid government support. Investors utilize this indicator to determine the timing of the company's commercial success.